Imatinib (Gleevec, Novartis, Basel, Switzerland), formerly referred to as STI571, is an inhibitor of specific protein tyrosine kinases that was targeted to the platelet-derived growth factor (PDGF ...

Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference. The study ...

July 26, 2006 —The cardiotoxic effects related to the leukemia drug imatinib ( Gleevec in the United States, Glivec elsewhere; Novartis) "is a big surprise," says the researcher heading the team ...

DFS at 3 years increased from 55% with 3 years of imatinib maintenance to 87% with 6 years of maintenance therapy. Patients with an estimated 35-70% risk of relapse derived the most benefit from ...

Painful crises in sickle cell disease or sickle cell anemia could potentially be treated using imatinib as a therapeutic option, a small study found. Painful crises that occur in patients with ...

Eligible patients were treated daily with imatinib dosed at 300 mg twice a day (for body-surface area ≥ 1.5 m 2). The primary end point was response (clinical benefit response [CBR]), defined as ...

Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa.